T. Rowe Price Investment Management, Inc. Morpho Sys Ag Transaction History

T. Rowe Price Investment Management, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$4.55 - $9.9 $5.71 Million - $12.4 Million	-1,255,796 Reduced 16.34%	6,431,063 $63.7 Million
Q3 2023 Nov 14, 2023	SELL	$6.72 - $8.6 $491,688 - $629,244	-73,168 Reduced 0.94%	7,686,859 $51.7 Million
Q2 2023 Aug 14, 2023	BUY	$3.95 - $7.74 $659,223 - $1.29 Million	166,892 Added 2.2%	7,760,027 $58 Million
Q1 2023 May 15, 2023	BUY	$3.56 - $5.22 $1.12 Million - $1.64 Million	315,037 Added 4.33%	7,593,135 $30 Million
Q4 2022 Feb 14, 2023	BUY	$3.21 - $5.74 $23.4 Million - $41.8 Million	7,278,098 New	7,278,098 $26.1 Million

1.8M

14.7K

Ticker MOR
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 136,614,000
Description
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...

Get notified when there are updates to the investment portfolio of T. Rowe Price Investment Management, Inc., based on Form 13F filings with the SEC.

Stay updated on T. Rowe Price Investment Management, Inc. with notifications on news.